Group 1 - The amino acid industry is experiencing a multi-field demand resonance, driven by technological upgrades and high-end transformation, with domestic companies like Wuxi Jinghai accelerating breakthroughs in high-end pharmaceutical raw materials [3][11][23] - The global amino acid production scale surpassed 10 million tons in 2021 and is expected to reach 13.8 million tons by 2027, while the global market size was $26.19 billion in 2021 and is projected to grow to $49.42 billion by 2030 [17][19][22] - Amino acids are widely used in pharmaceuticals, agriculture, health care, food feed, and cosmetics, with applications expanding due to increasing public awareness of health and nutrition [3][20][21] Group 2 - The North Exchange chemical new materials industry experienced a decline of 1.62% in the week from September 15 to September 19, 2025, with various sub-industries showing different levels of decrease [4][25][26] - Key stocks in the North Exchange chemical new materials sector that performed well during the week included Sanwei Equipment (+22.53%), Hanwei Technology (+15.26%), and Huitong New Materials (+5.68%) [33][35] - The overall performance of the North Exchange chemical new materials industry was weak, with all sub-industries experiencing declines, including battery materials (-3.93%) and non-metal materials (-4.36%) [26][30][32]

Investment Rating - The report maintains a "Strong Buy" rating for the company, with a target price of 14.64 CNY [2][7]. Core Insights - The company's performance in H1 2025 met expectations, with a revenue of 12.28 billion CNY, a year-on-year decrease of 2.87%, and a net profit of 1.768 billion CNY, an increase of 19.96% year-on-year [7]. - The amino acid sector showed resilience, with diversified procurement strategies mitigating raw material price fluctuations [7]. - The company is accelerating its international expansion, enhancing its capabilities in the pharmaceutical amino acid market [7]. - A strong commitment to shareholder returns is evident, with a total cash dividend of 1.699 billion CNY for 2024, representing 83% of the annual net profit [7]. Financial Forecast - Projected total revenue for 2024 is 25.069 billion CNY, with a year-on-year growth rate of -9.7%. For 2025, revenue is expected to reach 27.243 billion CNY, reflecting an 8.7% growth [3][8]. - The forecasted net profit for 2025 is 3.142 billion CNY, a 14.6% increase from the previous year [3][8]. - Earnings per share (EPS) are projected to be 1.10 CNY for 2025, with a price-to-earnings (P/E) ratio of 10.1 [3][8]. Market Position and Strategy - The company is positioned as a leader in the amino acid industry, with a strategy focused on global expansion and product diversification [7]. - Recent changes in trade tariffs, particularly a reduction in anti-dumping duties by the EU, are expected to positively impact the company's competitive position [7]. - The company has successfully established overseas bases and obtained necessary certifications, enhancing its global competitiveness [7].